Glycan Mimetics from Natural Products : New Therapeutic Opportunities for Neurodegenerative Disease
(2019) In Molecules (Basel, Switzerland) 24(24).- Abstract
- Neurodegenerative diseases (NDs) affect millions of people worldwide.
Characterized by the functional loss and death of neurons, NDs lead to
symptoms (dementia and seizures) that affect the daily lives of
patients. In spite of extensive research into NDs, the number of
approved drugs for their treatment remains limited. There is therefore
an urgent need to develop new approaches for the prevention and
treatment of NDs. Glycans (carbohydrate chains) are ubiquitous,
abundant, and structural complex natural biopolymers. Glycans often
covalently attach to proteins and lipids to regulate cellular
recognition, adhesion, and signaling. The importance of glycans in both
the developing and mature... (More) - Neurodegenerative diseases (NDs) affect millions of people worldwide.
Characterized by the functional loss and death of neurons, NDs lead to
symptoms (dementia and seizures) that affect the daily lives of
patients. In spite of extensive research into NDs, the number of
approved drugs for their treatment remains limited. There is therefore
an urgent need to develop new approaches for the prevention and
treatment of NDs. Glycans (carbohydrate chains) are ubiquitous,
abundant, and structural complex natural biopolymers. Glycans often
covalently attach to proteins and lipids to regulate cellular
recognition, adhesion, and signaling. The importance of glycans in both
the developing and mature nervous system is well characterized.
Moreover, glycan dysregulation has been observed in NDs such as
Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease
(PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
Therefore, glycans are promising but underexploited therapeutic
targets. In this review, we summarize the current understanding of
glycans in NDs. We also discuss a number of natural products that
functionally mimic glycans to protect neurons, which therefore represent
promising new therapeutic approaches for patients with NDs. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b1c49a25-9b06-4638-897e-c9b44b917f51
- author
- Wang, Wenyue
; Gopal, Sandeep
LU
; Pocock, Roger and Xiao, Zhicheng
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- keywords
- Animals, Biological Mimicry, Biological Products/chemistry, Biomimetics/methods, Drug Discovery/methods, Glycosylation, Humans, Molecular Structure, Neurodegenerative Diseases/drug therapy, Polysaccharides/biosynthesis
- in
- Molecules (Basel, Switzerland)
- volume
- 24
- issue
- 24
- article number
- 4604
- publisher
- MDPI AG
- external identifiers
-
- pmid:31888221
- scopus:85076632493
- ISSN
- 1420-3049
- DOI
- 10.3390/molecules24244604
- language
- English
- LU publication?
- no
- id
- b1c49a25-9b06-4638-897e-c9b44b917f51
- date added to LUP
- 2021-10-25 12:56:52
- date last changed
- 2024-06-15 18:54:39
@article{b1c49a25-9b06-4638-897e-c9b44b917f51, abstract = {{Neurodegenerative diseases (NDs) affect millions of people worldwide. <br> Characterized by the functional loss and death of neurons, NDs lead to <br> symptoms (dementia and seizures) that affect the daily lives of <br> patients. In spite of extensive research into NDs, the number of <br> approved drugs for their treatment remains limited. There is therefore <br> an urgent need to develop new approaches for the prevention and <br> treatment of NDs. Glycans (carbohydrate chains) are ubiquitous, <br> abundant, and structural complex natural biopolymers. Glycans often <br> covalently attach to proteins and lipids to regulate cellular <br> recognition, adhesion, and signaling. The importance of glycans in both <br> the developing and mature nervous system is well characterized. <br> Moreover, glycan dysregulation has been observed in NDs such as <br> Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease<br> (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).<br> Therefore, glycans are promising but underexploited therapeutic <br> targets. In this review, we summarize the current understanding of <br> glycans in NDs. We also discuss a number of natural products that <br> functionally mimic glycans to protect neurons, which therefore represent<br> promising new therapeutic approaches for patients with NDs.}}, author = {{Wang, Wenyue and Gopal, Sandeep and Pocock, Roger and Xiao, Zhicheng}}, issn = {{1420-3049}}, keywords = {{Animals; Biological Mimicry; Biological Products/chemistry; Biomimetics/methods; Drug Discovery/methods; Glycosylation; Humans; Molecular Structure; Neurodegenerative Diseases/drug therapy; Polysaccharides/biosynthesis}}, language = {{eng}}, number = {{24}}, publisher = {{MDPI AG}}, series = {{Molecules (Basel, Switzerland)}}, title = {{Glycan Mimetics from Natural Products : New Therapeutic Opportunities for Neurodegenerative Disease}}, url = {{http://dx.doi.org/10.3390/molecules24244604}}, doi = {{10.3390/molecules24244604}}, volume = {{24}}, year = {{2019}}, }